Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Investigation

• Publication date

  1998-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI2038PMID 9502779PMCID PMC508692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin 12 and tumor necrosis factor a are costimulators of interferon y production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist

  2005cited by this paper
• A PHASE II STUDY OF DAILY SUBCUTANEOUS (SQ) LOW DOSE INTERLEUKIN-2(IL-2) IN HIV-ASSOCIATED MALIGNANCIES.: 96

  1997cited by this paper
• Regulation of interleukin‐12 receptor β1 chain expression and interleukin‐12 binding by human peripheral blood mononuclear cells

  1997cited by this paper
• HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

  1997cited by this paper
• CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin‐2 and the c‐kit ligand

  1997cited by this paper
• Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response.

  1997cited by this paper
• The expanding universe of T-cell subsets: Th1, Th2 and more.

  1996cited by this paper
• Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement

  1996cited by this paper
• Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

  1996cited by this paper
• The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells

  1996cited by this paper
• Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection.

  1996cited by this paper
• A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection.

  1996cited by this paper
• HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines.

  1995cited by this paper
• Biology of human TH1 and TH2 cells

  1995cited by this paper
• Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

  1995cited by this paper
• Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

  1994cited by this paper
• Cell preparation for the identification of leukocytes.

  1994cited by this paper
• Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells.

  1994cited by this paper
• Impaired interleukin 12 production in human immunodeficiency virus- infected patients

  1994cited by this paper
• The Th1-Th2 hypothesis of HIV infection: new insights.

  1994cited by this paper
• Interferon-gamma and host antimicrobial defense: current and future clinical applications.

  1994cited by this paper
• Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells.

  1994cited by this paper
• Human immunodeficiency virus and acquired immunodeficiency syndrome: an update.

  1994cited by this paper
• Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals.

  1994cited by this paper
• Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

  1993cited by this paper
• The T cell receptor V beta repertoire in HIV-1 infection and disease.

  1993cited by this paper
• Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

  1993cited by this paper
• Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

  1993cited by this paper
• Interferon gamma inhibits interleukin 10 production by monocytes

  1993cited by this paper
• Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice

  1993cited by this paper
• The T cell receptor Vβ repertoire in HIV-1 infection and disease

  1993cited by this paper
• The role of natural killer cells in innate resistance to infection.

  1993cited by this paper
• Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

  1993cited by this paper
• Constructing polycompetitor cDNAs for quantitative PCR.

  1993cited by this paper
• Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.

  1993cited by this paper
• Programmed death of T cells in HIV-1 infection.

  1992cited by this paper
• Cell preparation for the identification of leukocytes.

  1990cited by this paper

• Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals

  2020cites this paper
• Low‐dose IL‐2 induces CD56bright NK regulation of T cells via NKp44 and NKp46

  2020cites this paper
• The Mediation of miR-34a/miR-449c for Immune Cytokines in Acute Cold/Heat-Stressed Broiler Chicken

  2020cites this paper
• Mystery Solved: IL-15

  2019cites this paper
• Optimization of Cloning Conditions for High-level Production of Recombinant Mouse Interleukin-2 in Escherichia coli

  2019cites this paper
• Astaxanthin, a Carotenoid, Stimulates Immune Responses by Enhancing IFN-γ and IL-2 Secretion in Primary Cultured Lymphocytes in Vitro and ex Vivo

  2015cites this paper
• Deoxynivalenol-induced cytokines and related genes in concanavalin A-stimulated primary chicken splenic lymphocytes.

  2015cites this paper
• Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer

  2014cites this paper
• Nitric Oxide and Inflammation

  2012cites this paper
• Monitoring cytokine profiles during immunotherapy.

  2010cites this paper
• Interleukin-2 for Nonmelanoma Skin Cancer

  2010cites this paper
• Kidney transplant: graft and recipient profiling

  2009cites this paper
• - 1T cell Function in Patients with Dilated Cardiomyopathy

  2008cites this paper
• Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

  2008cites this paper
• T cell Function in Patients with Dilated Cardiomyopathy

  2008cites this paper
• Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.

  2008cites this paper
• Experimental Models of Cytokines and Cancer Prevention

  2007cites this paper
• Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393.

  2007cites this paper
• Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer

  2006cites this paper
• Natural Killer Cell Function Is Well Preserved in Asymptomatic Human Immunodeficiency Virus Type 2 (HIV-2) Infection but Similar to That of HIV-1 Infection When CD4 T-Cell Counts Fall

  2006cites this paper
• Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma: Cancer and Leukemia Group B 509901

  2006cites this paper
• APhase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIVand Cancer

  2006cites this paper
• A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer

  2006cites this paper
• Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice

  2005cites this paper
• Interleukin-2, interleukin-15, and their roles in human natural killer cells.

  2005cites this paper
• Overview of interleukin-2 function, production and clinical applications.

  2004cites this paper
• What Is Going on with Natural Killer Cells in HIV Infection?

  2004cites this paper
• Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

  2004cites this paper
• Interleukin-2 and cancer: critical analysis of results, problems and expectations.

  2003cites this paper
• AIDS-associated malignancies.

  2003cites this paper
• Interleukin-2 for the Treatment of HIV Infection

  2003cites this paper
• Sustained Suppression of HCV Replication and Inflammatory Activity After Interleukin‐2 Therapy in Patients With HIV/Hepatitis C Virus Coinfection

  2002cites this paper
• Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)

  2002cites this paper
• IL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patients.

  2002influential citation
• Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.

  2002cites this paper
• New targets for the treatment of advanced non-small cell lung cancer.

  2002cites this paper
• Systemic immune parameters and sleep after ultra-low dose administration of IL-2 in healthy men.

  2002cites this paper
• Type 1/Type 2 immunity in infectious diseases.

  2001cites this paper
• Deoxynivalenol-induced immunomodulation of human lymphocyte proliferation and cytokine production.

  2001cites this paper
• Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.

  2001cites this paper
• Long‐term immunotherapy with low‐dose interleukin‐2 and interferon‐α in the treatment of patients with advanced renal cell carcinoma

  2001cites this paper
• Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency.

  2001cites this paper
• Interleukin‐2 induced immune effects in human immunodeficiency virus‐infected patients receiving intermittent interleukin‐2 immunotherapy

  2001cites this paper
• Cytokines and Chemokines in HIV Infection

  2001cites this paper
• Nitric oxide as a mediator of interleukin-2 induced cardiovascular toxicity and antitumor activity

  2001cites this paper
• Prospects for IL-16 in the treatment of AIDS

  2001cites this paper
• Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications

  2001cites this paper
• Interleukin 15: biology and relevance to human disease.

  2001cites this paper
• Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

  2000cites this paper
• Computational Model for Effects of Ligand/Receptor Binding Properties on Interleukin‐2 Trafficking Dynamics and T Cell Proliferation Response

  2000cites this paper
• The cytokine milieu of HIV-associated non-Hodgkin's lymphoma favours aggressive tumours.

  2000cites this paper
• Differential regulation in human amnion epithelial and fibroblast cells of prostaglandin E(2) production and prostaglandin H synthase-2 mRNA expression by dexamethasone but not tumour necrosis factor-alpha.

  2000cites this paper
• Polymorphisms of the human IFNG gene noncoding regions

  2000cites this paper
• Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: the rationale for low-dose interleukin-2 therapy.

  2000cites this paper
• Increased Endosomal Sorting of Ligand to Recycling Enhances Potency of an Interleukin-2 Analog*

  2000cites this paper
• Interleukin-2 treatment of microglia has no effect on in vitro HIV infection.

  1999cites this paper
• Activation of NF-kappaB in Mycobacterium tuberculosis- induced interleukin-2 receptor expression in mononuclear phagocytes.

  1999cites this paper
• Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.

  1999cites this paper
• Intravenous Cytokine Gene Delivery by Lipid-DNA Complexes Controls the Growth of Established Lung Metastases

  1999cites this paper
• Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

  1999cites this paper
• Cytokines in the evolution and treatment of AIDS-lymphoma.

  1999cites this paper
• Innate Immune Response Combination with IL-12: Implications for the Activation with IL-18 or IL-15 in Expression by Human NK Cells Following Differential Cytokine and Chemokine Gene

  1999cites this paper
• Regulation and Function of T-Cell-Mediated Immunity during Toxoplasma gondii Infection

  1998cites this paper
• This information is current as Infection Produce C-C Chemokines and Inhibit HIV-1 Patients + Natural Killer Cells from HIV-1

  1998cites this paper
• Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay

  1998cites this paper
• Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.

  1998cites this paper